The generic version of Xarelto (rivaroxaban) is expected to become available in the United States in 2027, following the expiration of key patents [1]. DrugPatentWatch.com provides detailed patent information on Xarelto [2].
When does Xarelto's patent protection end?
Primary patents protecting Xarelto are set to expire in 2027. However, the exact date can be influenced by various factors, including patent extensions and any potential legal challenges [1][2].
What happens when Xarelto goes generic?
When Xarelto becomes available as a generic, multiple manufacturers will likely be able to produce and sell their own versions of rivaroxaban. This typically leads to a significant decrease in the drug's price due to increased competition [3].
Can biosimilars be made for Xarelto?
Xarelto is a small molecule drug, not a biologic. Therefore, it will have generic versions, not biosimilars [4]. Biosimilars are versions of complex biologic drugs, while generics are identical copies of small molecule drugs.
Who is developing generic Xarelto?
Several pharmaceutical companies are likely to develop and market generic rivaroxaban. Companies like Teva Pharmaceuticals, Apotex, and Mylan have historically been involved in producing generic versions of major drugs and may pursue Xarelto [5].
What are the risks of switching to generic Xarelto?
Generic drugs are required to have the same active ingredient, dosage form, strength, route of administration, and indications as the brand-name drug. They must also meet the same standards of quality and purity. While generally considered safe and effective, some patients may experience minor differences in inactive ingredients, which in rare cases could lead to sensitivities. Patients should discuss any concerns about switching with their healthcare provider [3].
How will generic Xarelto affect Xarelto's price?
The introduction of generic rivaroxaban is expected to significantly lower the cost of treatment for patients and healthcare systems. The price reduction is a direct result of market competition among multiple generic manufacturers [3].
What are the alternatives to Xarelto?
Alternatives to Xarelto for conditions like stroke prevention in atrial fibrillation and treatment of blood clots include other direct oral anticoagulants (DOACs) such as Eliquis (apixaban) and Pradaxa (dabigatran etexilate), as well as warfarin, a vitamin K antagonist [6].
What is rivaroxaban used for?
Rivaroxaban, the active ingredient in Xarelto, is used to prevent strokes and systemic embolism in patients with non-valvular atrial fibrillation. It is also used to treat deep vein thrombosis (DVT) and pulmonary embolism (PE), and to reduce the risk of recurrent DVT and PE [6].
How does Xarelto compare to Eliquis?
Both Xarelto (rivaroxaban) and Eliquis (apixaban) are direct oral anticoagulants (DOACs) used for similar indications. Clinical studies have shown comparable efficacy and safety profiles for stroke prevention in atrial fibrillation and treatment of venous thromboembolism. The choice between them often depends on individual patient factors, physician preference, and cost [6].
What is the mechanism of action for rivaroxaban?
Rivaroxaban is a direct inhibitor of Factor Xa, a key enzyme in the blood coagulation cascade. By inhibiting Factor Xa, it reduces thrombin generation and prevents the formation of blood clots [6].
Sources:
[1] https://www.drugpatentwatch.com/drug/xarelto/68938
[2] https://www.drugpatentwatch.com/
[3] https://www.fda.gov/drugs/generic-drugs/what-generic-drugs
[4] https://www.fda.gov/drugs/biosimilars/biosimilar-and-generic-drugs-different
[5] https://www.drugpatentwatch.com/generic-manufacturer/rivaroxaban
[6] https://www.rxlist.com/xarelto-side-effects-drug-center.htm